MedTrace Logo

Phase 1/2 Study of TAK-850 Subcutaneous Injection in Healthy Adults

NCT02313155 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2016-02-17

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety and immunogenicity of a single subcutaneous injection of TAK-850 as compared to intramuscular injection of TAK-850 in healthy Japanese adults

Conditions

  • Influenza Infection

Interventions

DRUG

Subcutaneous injection of TAK-850

TAK-850 0.5 mL, Subcutaneous injection

DRUG

Intramuscular injection of TAK-850

TAK-850 0.5 mL, Intramuscular injection

Sponsors & Collaborators

Principal Investigators

  • Senior VP Clinical Science · Takeda

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
49 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2015-01-31
Completion
2015-01-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02313155 on ClinicalTrials.gov